Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Swiss Exchange  >  Novartis    NOVN   CH0012005267

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets
The feature you requested does not exist. However, we suggest the following feature:

Novartis : entices UCSF director to senior position at NIBR

share with twitter share with LinkedIn share with facebook
share via e-mail
08/19/2017 | 10:27am CEST

The director of UCSF`s Cardiovascular Research Institute (CRI)Shaun Coughlin, M.D., Ph.D.has joined the ranks of senior academics heading to drugmaker Novartis.

The MIT and Harvard-educated professor is joining Novartis, taking the role of global head of cardiovascular and metabolism at the Novartis Institutes for BioMedical Research (NIBR), the network of R&D facilities in Europe, the U.S. and China that the company describes as its "innovation engine."

Coughlin will take up the position based at NIBR`s Cambridge, Massachusetts, campus on Nov. 1. It`s the latest in a series of appointments at Novartis that have put prominent academics in charge of R&D units at NIBR.

Former NIBR director Mark Fishman, M.D., who himself left the role of head of cardiology at Massachusetts General to head the organization for 13 years before stepping down in 2015, made hiring academic starts a feature of his tenure.

He recruited Stanford`s Ricardo Dolmetsch, Ph.D., to lead NIBR`s neuroscience activities in 2013, and two years later he brought in Dana-Farber Cancer Institute immunologist Glenn Dranoff, M.D., Ph.D., to head up its immuno-oncology efforts. That year he also recruited prominent Dana-Farber and Harvard scientist Jay Bradner, M.D., as his successor.

And the policy has continued since Bradner replaced Fishman. Last year, Novartis named Peter Hammerman, M.D., Ph.D., global head of oncology translational research and Jeff Engelman, M.D., Ph.D., as global head of oncology research, both of whom moved to the NIBR from Harvard.

Coughlin joins NIBR after more than 30 years at UCSF, serving as head of the CRI since 1997 and specializing in signaling mechanisms in cardiovascular biology and disease. He`s no stranger to the pharma industry either, having held director-level positions at Gorilla Genomics, Millennium Pharmaceuticals and COR Therapeutics.

According to an Endpoints report, the dean of UCSF Medical School, Talmadge King, M.D., said Coughlin`s research at UCSF "revealed a mechanism by which proteases regulate cellular behaviors including a key mechanism that controls blood platelet activation and clot formation. This work led to a new medical therapy for preventing heart attacks and strokes and has been honored by the American Heart Association`s Basic Science Award in 2003 and its Research Achievement Award in 2014."

(c) 2017 TBREAK MEDIA. ALL RIGHTS RESERVED. Provided by SyndiGate Media Inc. (Syndigate.info)., source Middle East & North African Newspapers

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on NOVARTIS
08/19 NOVARTIS : entices UCSF director to senior position at NIBR
08/17 NOVARTIS : Argentum Pharmaceuticals Succeeds in Starting Patent Cancellation Tri..
08/17 NOVARTIS : Cell Therapy Pioneer David Epstein Expands Role with Rubius Therapeut..
08/17 NEW CHEMICAL RESEARCH STUDY FINDINGS : Exploring Molecular Data Sets Using a Com..
08/17 NOVARTIS : Studies from Novartis Yield New Information about Algorithms (Prelimi..
08/15 NOVARTIS : $87,100 Federal Contract Awarded to Alcon Laboratories
08/10 NOVARTIS : "Solid Pharmaceutical Composition Comprising PI3K-Inhibitor" in Paten..
08/10 NOVARTIS : Patent Issued for Poly(Oxazoline-Co-Ethyleneimine)-Epichlorohydrin Co..
08/10 NOVARTIS : Patent Issued for Polymerizable Polysiloxanes with Hydrophilic Substi..
08/10 NOVARTIS : Data on Eicosanoids Reported by Researchers at Novartis [Absorption, ..
More news
News from SeekingAlpha
08/18 Pfizer Looks To Sneak In the Market Before Heavy Hitters
08/18 Buy Novartis Under $80 - Cramer's Lightning Round (8/17/17)
08/16 CONATUS : Major Contender For The NASH Market
08/16 Biogen's Alzheimer's Hope Tops The Sector's Most Valuable Pipeline Projects
08/16 NOVARTIS : Why Entresto Is Key
Financials ($)
Sales 2017 48 668 M
EBIT 2017 11 971 M
Net income 2017 7 307 M
Debt 2017 15 947 M
Yield 2017 3,45%
P/E ratio 2017 23,78
P/E ratio 2018 20,97
EV / Sales 2017 4,78x
EV / Sales 2018 4,58x
Capitalization 216 915 M
Duration : Period :
Novartis Technical Analysis Chart | NOVN | CH0012005267 | 4-Traders
Technical analysis trends NOVARTIS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 32
Average target price 87,3 $
Spread / Average Target 5,5%
EPS Revisions
Joseph Jimenez Chief Executive Officer
Hans Jörg Reinhardt Independent Non-Executive Chairman
Harry Kirsch Chief Financial Officer
Vasant Narasimhan Chief Medical Officer & Head-Drug Development
Srikant Madhav Datar Independent Non-Executive Director
Sector and Competitors
1st jan.Capitalization (M$)
NOVARTIS7.69%216 915
JOHNSON & JOHNSON15.12%355 979
ROCHE HOLDING LTD.3.78%216 699
PFIZER0.59%194 554
SANOFI6.97%122 127